About this trial
Every new classification depends on its prognostic power and on the type of treatment given. With the rapid evolution of diagnostic methods and the advance in new treatments, there is much less reliable information available on how patients with newly defined brain tumour entities should be treated and what to expect from the current treatments.
The goal is to determine whether the new 2021 WHO classification, based on cIMPACT-NOW recommendations, results in more homogeneous patient groups than the old 2016 classification. Furthermore, it will help derive provisional guidelines on how patients with these newly defined tumour entities are best treated. These recommendations will be based on the experience of EORTC investigators with chosen treatments and their experience as reported in this data collection report.
Eligibility criteria
Qualifiers
Age ≥ legal age of consent
Newly diagnosed or recurrent primary brain tumours within one of the 17 cohorts of interest
Archival tumour tissue from primary tumour available at the site. Representative tissue from first surgery is preferred, but tissue from surgery for recurrence is allowed. Exception: only tissue from first surgery is allowed for Cohort 16.
Available MRI/CT scans from primary brain tumour at initial diagnosis
Disqualifiers
None
Trial design
Treatments tested in this trial
- Observational
Treatment groups
17
Treatment groupsSee each treatment group below.
Locations
42Sponsors and collaborators
European Organisation for Research and Treatment of Cancer - EORTC
Lead sponsor